{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T18:21:26Z","timestamp":1793989286998,"version":"4.8.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":6542,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["intpsychogeriatrics.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Psychogeriatrics"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1017\/s1041610207005790","type":"journal-article","created":{"date-parts":[[2007,8,15]],"date-time":"2007-08-15T14:13:42Z","timestamp":1187187222000},"page":"67-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia"],"prefix":"10.1016","volume":"20","author":[{"given":"Stefan","family":"Lorenzl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"B\u00fcerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Hampel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Flint","family":"Beal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1017\/S1041610207005790_bb0010","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1161\/01.STR.0000127420.10990.76","article-title":"Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease","volume":"35","author":"Adair","year":"2004","journal-title":"Stroke"},{"key":"10.1017\/S1041610207005790_bb0015","first-page":"60","article-title":"Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain","volume":"20","author":"Asahina","year":"2001","journal-title":"Clinical Neuropathology"},{"key":"10.1017\/S1041610207005790_bb0020","doi-asserted-by":"crossref","first-page":"7910","DOI":"10.1523\/JNEUROSCI.16-24-07910.1996","article-title":"Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1\u201340)","volume":"16","author":"Backstrom","year":"1996","journal-title":"Journal of Neuroscience"},{"key":"10.1017\/S1041610207005790_bb0025","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0167-4838(99)00279-4","article-title":"Tissue inhibitors of metalloproteinases: evolution, structure and function","volume":"1477","author":"Brew","year":"2000","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1017\/S1041610207005790_bb0030","doi-asserted-by":"crossref","unstructured":"Frank R. A. 2003. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiology of Aging, 24: 521\u2013536. DOI: 10.1016\/S0197-4580(03)00002-2.","DOI":"10.1016\/S0197-4580(03)00002-2"},{"key":"10.1017\/S1041610207005790_bb0035","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.61.1.95","article-title":"Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer's disease \u2013 a comparative CSF study","volume":"61","author":"Hampel","year":"2004","journal-title":"Archives of General Psychiatry"},{"key":"10.1017\/S1041610207005790_bb0040","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00702-003-0065-z","article-title":"Core biological marker candidates of Alzheimer's disease \u2013 perspectives for diagnosis, prediction of outcome and reflection of biological activity","volume":"111","author":"Hampel","year":"2004","journal-title":"Journal of Neural Transmission"},{"key":"10.1017\/S1041610207005790_bb0045","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0304-3940(03)00905-4","article-title":"The role of matrix metalloproteinase-9 in dementia","volume":"350","author":"Helbecque","year":"2003","journal-title":"Neuroscience Letters"},{"key":"10.1017\/S1041610207005790_bb0050","doi-asserted-by":"crossref","first-page":"24360","DOI":"10.1074\/jbc.273.38.24360","article-title":"Plasma membrane-bound tissue inhibitor of metalloproteinases (TIMP)-2 specifically inhibits matrix metalloproteinase 2 (gelatinase A) activated on the cell surface","volume":"273","author":"Itoh","year":"1998","journal-title":"Biological Chemistry"},{"key":"10.1017\/S1041610207005790_bb0055","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0014-5793(03)01094-9","article-title":"Selective involvement of TIMP-2 in the second activational cleavage of pro-MMP-2: refinement of the pro-MMP-2 activation mechanism","volume":"553","author":"LaFleur","year":"2003","journal-title":"FEBS Letters"},{"key":"10.1017\/S1041610207005790_bb0060","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0304-3940(00)01418-X","article-title":"Brain matrix metalloproteinase 1 levels are elevated in Alzheimer's disease","volume":"291","author":"Leake","year":"2000","journal-title":"Neuroscience Letters"},{"key":"10.1017\/S1041610207005790_bb0065","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/brain\/122.2.191","article-title":"Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study","volume":"122","author":"Lee","year":"1999","journal-title":"Brain"},{"key":"10.1017\/S1041610207005790_bb0070","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0197-0186(03)00004-4","article-title":"Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease","volume":"43","author":"Lorenzl","year":"2003","journal-title":"Neurochemistry International"},{"key":"10.1017\/S1041610207005790_bb0075","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1136\/jnnp.57.4.416","article-title":"Clinical and neuropathological criteria for frontotemporal dementia","volume":"57","author":"Lund and Manchester Groups","year":"1994","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1017\/S1041610207005790_bb0080","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1017\/S1041610207005790_bb0085","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1212\/WNL.54.5.1050","article-title":"Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies","volume":"54","author":"McKeith","year":"2000","journal-title":"Neurology"},{"key":"10.1017\/S1041610207005790_bb0090","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1212\/WNL.39.9.1159","article-title":"The consortium to establish a registry for Alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease","volume":"39","author":"Morris","year":"1989","journal-title":"Neurology"},{"key":"10.1017\/S1041610207005790_bb0095","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/00005072-199501000-00002","article-title":"Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain","volume":"54","author":"Peress","year":"1995","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"key":"10.1017\/S1041610207005790_bb0100","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: clinical characterization and outcome","volume":"56","author":"Petersen","year":"1999","journal-title":"Archives of Neurology"},{"key":"10.1017\/S1041610207005790_bb0105","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1001\/archneur.59.6.972","article-title":"Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease","volume":"59","author":"Pratico","year":"2002","journal-title":"Archives of Neurology"},{"key":"10.1017\/S1041610207005790_bb0110","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0197-4580(03)00031-9","article-title":"Plasma antioxidants are similary depleted in mild cognitive impairment and in Alzheimer's disease","volume":"24","author":"Rinaldi","year":"2003","journal-title":"Neurobiology of Aging"},{"key":"10.1017\/S1041610207005790_bb0115","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/01.STR.32.5.1162","article-title":"White matter damage is associated with matrix metalloproteinases in vascular dementia","volume":"32","author":"Rosenberg","year":"2001","journal-title":"Stroke"},{"key":"10.1017\/S1041610207005790_bb0120","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2174\/0929867013372922","article-title":"Chemistry and biochemistry of oxidative stress in neurodegenerative disease","volume":"8","author":"Sayre","year":"2001","journal-title":"Current Medical Chemistry"},{"key":"10.1017\/S1041610207005790_bb0125","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nm0896-864","article-title":"Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease","volume":"2","author":"Scheuner","year":"1996","journal-title":"Nature Medicine"},{"key":"10.1017\/S1041610207005790_bb0130","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0002-9440(10)61727-0","article-title":"Proteolysis of AA amyloid fibrils by matrix metalloproteinases-1, -2, and -3","volume":"159","author":"Stix","year":"2001","journal-title":"American Journal of Pathology"},{"key":"10.1017\/S1041610207005790_bb0135","first-page":"121","article-title":"The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes. Transcriptional and posttranscriptional regulation, signal transduction and cell-type-specific expression","volume":"151","author":"Vincenti","year":"2001","journal-title":"Methods in Molecular Biology"},{"key":"10.1017\/S1041610207005790_bb0140","doi-asserted-by":"crossref","first-page":"24566","DOI":"10.1074\/jbc.M602440200","article-title":"Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ","volume":"281","author":"Yan","year":"2006","journal-title":"Journal of Biological Chemistry"}],"container-title":["International Psychogeriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610224051913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610224051913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1041610207005790","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T17:58:54Z","timestamp":1744394334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1041610224051913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S1041610224051913"],"URL":"https:\/\/doi.org\/10.1017\/s1041610207005790","relation":{},"ISSN":["1041-6102"],"issn-type":[{"value":"1041-6102","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia","name":"articletitle","label":"Article Title"},{"value":"International Psychogeriatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1017\/S1041610207005790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Copyright \u00a9 International Psychogeriatric Association 2007. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}